Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The brain tumor microenvironment primes metastatic cells for resistance to targeted therapies

ABSTRACT: The brain tumor microenvironment primes metastatic cells for resistance to targeted therapies

PROVIDER: PRJNA731909 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14615124_1.fastq.gz	Fastqsanger.gz
	SRR14615124_2.fastq.gz	Fastqsanger.gz
	SRR14615125_1.fastq.gz	Fastqsanger.gz
	SRR14615125_2.fastq.gz	Fastqsanger.gz
	SRR14615126_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 70

Similar Datasets

The brain tumor microenvironment primes metastatic cells for resistance to targeted therapies

Project description:The brain is a major sanctuary site for metastatic lung cancer cells that evade systemic therapies. We performed pharmacological, biological, and molecular studies to identify the functional link between drug resistance and central nervous system (CNS) relapse in late-stage EGFR mutant non-small cell lung cancer, which frequently progresses in the brain even when treated with the brain penetrant EGFR inhibitor osimertinib. Despite widespread osimertinib distribution in vivo, the brain microvascular tumor microenvironment (TME) is associated with the persistence of malignant cell sub-populations which are poised to further proliferate in the brain as osimertinib-resistant lesions over time. Cellular and molecular features of this poised state are commonly regulated through RhoA signaling, which potentiates the outgrowth of disseminated tumor cells on osimertinib treatment, preferentially in response to extracellular laminin and in the brain. Thus, we identify pre-existing and adaptive features of metastatic and drug resistant cancer cells, which are enhanced by RhoA and the brain TME during the evolution of osimertinib resistant disease.

2022-09-02 | GSE174850 | GEO

Resistance to targeted therapies in the brain tumor microenvironment is not drive by genetic mutations

2022-09-02 | GSE174852 | GEO

Resistance to targeted therapies in the brain tumor microenvironment occurs through selection of cells with distinct transcriptomic profiles

2022-09-02 | GSE174851 | GEO

Resistance to targeted therapies in the brain tumor microenvironment is not drive by genetic mutations

Project description:Resistance to targeted therapies in the brain tumor microenvironment is not drive by genetic mutations

| PRJNA731911 | ENA

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies

Project description:Estrogen receptor positive (ER+) breast cancers that develop resistance to therapies that target the ER are the most common cause of breast cancer death. Beyond mutations in ER, which occur in 25-30% of patients treated with aromatase inhibitors (AIs), our understanding of clinical mechanisms of resistance to ER-directed therapies remains incomplete. We identified activating HER2 mutations in metastatic biopsies from eight patients with ER+ metastatic breast cancer who had developed resistance to ER-directed agents, including AIs, tamoxifen, and fulvestrant. Examination of treatment-naïve primary tumors in five patients revealed no evidence of pre-existing mutations in four of five patients, suggesting that these mutations were acquired under the selective pressure of ER-directed therapy. These mutations were mutually exclusive with ER mutations, suggesting a distinct mechanism of acquired resistance to ER-directed therapies. In vitro analysis confirmed that these mutations conferred estrogen independence. In addition, and in contrast to ER mutations, these mutations resulted in resistance to tamoxifen, fulvestrant, and the CDK4/6 inhibitor palbociclib. Resistance was overcome by combining ER-directed therapy with the irreversible HER2 kinase inhibitor neratinib, highlighting an effective treatment strategy in these patients.

2018-10-19 | GSE121411 | GEO

Molecular subtypes of metastatic colorectal cancer are predictive of patient response to chemo and targeted therapies (part 2)

Project description:We report that previously described molecular subtypes of colorectal cancer are associated with the response to therapy in patients with metastatic disease. We also identified a patient population with high FOLFIRI sensitivity, as indicated by their 2.7-fold longer overall survival when treated with FOLFIRI, as first-line regimen, instead of FOLFOX. Our results demonstrate the interest of molecular classifications to develop tailored therapies for patients with metastatic colorectal cancer.

2017-08-17 | GSE72969 | GEO

Molecular subtypes of metastatic colorectal cancer are predictive of patient response to chemo and targeted therapies (part 1)

2017-08-17 | GSE72968 | GEO

KMT2A oncoproteins induce epigenetic resistance to targeted therapies.

Project description:KMT2A oncoproteins induce epigenetic resistance to targeted therapies.

| PRJNA1060315 | ENA

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies

Project description:Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies

| PRJNA497449 | ENA

Resistance to targeted therapies in the brain tumor microenvironment occurs through selection of cells with distinct transcriptomic profiles

Project description:Resistance to targeted therapies in the brain tumor microenvironment occurs through selection of cells with distinct transcriptomic profiles

| PRJNA731910 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data